Compugen Ltd. announced on July 21, 2025, that the first patient was dosed in sub-trial 1 of its global adaptive platform trial, MAIA-ovarian. This trial is evaluating maintenance therapy with single agent COM701, a potential first-in-class anti-PVRIG antibody, in patients with relapsed platinum-sensitive ovarian cancer.
This trial addresses a significant unmet medical need for approximately 8,000 to 12,000 women who lack standard-of-care treatment options after progressing post-PARP inhibitors and/or bevacizumab. The trial is a double-blind, randomized placebo-controlled study enrolling 60 patients, with an interim analysis planned for the second half of 2026.
A clinically meaningful outcome is defined as a three-month improvement over the median progression-free survival (PFS) of the placebo arm, which typically stands at around six months. Positive data from this trial could support broader clinical development and facilitate discussions with regulatory authorities for potential single-agent registration, significantly expanding COM701's market opportunity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.